A detailed history of Abel Hall, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Abel Hall, LLC holds 482 shares of VRTX stock, worth $196,742. This represents 0.15% of its overall portfolio holdings.

Number of Shares
482
Previous 470 2.55%
Holding current value
$196,742
Previous $220 Million 1.76%
% of portfolio
0.15%
Previous 0.16%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$460.0 - $505.78 $5,520 - $6,069
12 Added 2.55%
482 $224 Million
Q2 2024

Jul 25, 2024

BUY
$392.81 - $485.53 $184,620 - $228,199
470 New
470 $220 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Abel Hall, LLC Portfolio

Follow Abel Hall, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abel Hall, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Abel Hall, LLC with notifications on news.